Abstract
L‐alanosine (NSC I5353) is a newly developed antitumor antibiotic which acts as an inhibitor of purine intermediary metabolism. Experimental antitumor activity was demonstrated in a variety of murine neoplasms. A phase I trial was undertaken on a daily × 5 (d × 5) schedule in 22 evaluable patients. Dose limiting toxicity was an oral mucositis characterized by beefy red oral, lingual and pharyngeal erythema. The maximum tolerated dose is 320 mg/m2/d × 5 every three weeks. The recommended dose for phase II evaluation is 160 mg/m2/d × 5 every three weeks. Copyright © 1983 American Cancer Society
Cite
CITATION STYLE
Goldsmith, M. A., Ohnuma, T., Spigelman, M., Greenspan, E. M., & Holland, J. F. (1983). Phase I study of L‐alanosine (NSC 15353). Cancer, 51(3), 378–380. https://doi.org/10.1002/1097-0142(19830201)51:3<378::AID-CNCR2820510303>3.0.CO;2-I
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
